Pasithea reports Phase 1 partial response for PAS-004 in advanced cancer; ALS Association awards $1M grant

Pasithea Therapeutics Corp.

BRAF V600E melanoma patient achieved -31.9% tumor reduction on PAS-004 monotherapy; remains on trial >11 months.
Overall disease control rate 71.4% in BRAF-mutated tumors; no DLTs or discontinuations across 27 patients.
PAS-004 tablet formulation shows 3-fold higher dose-normalized exposure vs capsule with less variability.
Cohort 7 (37mg capsule): zero TRAEs in DLT period; 80% pERK inhibition at Cmax; SRC clears escalation to 45mg.
ALS Association awards ~$1M grant for Phase 1 study of PAS-004 in 12 ALS patients (safety, ALSFRS-R, NfL).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.